Involvement of the peripheral nervous system in mitochondrial disorders has been previously reported. However, the prevalence of peripheral neuropathy in mitochondrial disorders is still unclear. Based on the large database of the "Nation-wide Italian Collaborative Network of Mitochondrial Diseases", we reviewed the clinical data of 1200 patients, with special regard to peripheral neuropathy (mean age at onset 24.3 ± 20.1 years; age at last evaluation 39.8 ± 22.3 years; females 52.7%; childhood onset [before age 16 years] 43.1%). Peripheral neuropathy was present in 143/1156 patients (12.4%), being one of the ten most common signs and symptoms. POLG mutations cause a potentially painful, axonal/mixed, mainly sensory polyneuropathy; TYMP mutations lead to a demyelinating sensory-motor polyneuropathy; SURF1 mutations are associated with a demyelinating/mixed sensory-motor polyneuropathy. The only mtDNA mutation consistently associated with peripheral neuropathy (although less severely than in the above-considered nuclear genes) was the m.8993T > G (or the rarer T > C) changes, which lead to an axonal, mainly sensory polyneuropathy. In conclusion, peripheral neuropathy is one of the most common features of a mitochondrial disorder, and may negatively impact on the quality of life of these patients. Furthermore, the presence or absence of peripheral neuropathy, as well as its specific forms and the association with neuropathic pain (indicative of a POLG-associated disease) can guide the molecular analysis.
The central task of mitochondria is to generate energy in the form of adenosine triphosphate, through the electron transport chain and oxidative phosphorylation (OXPHOS) [1] . This pathway is under control of both nuclear and mitochondrial (mtDNA) genomes. Mitochondrial diseases are a group of disorders caused by OXPHOS impairment. They are one of the commonest inherited neuromuscular diseases, with an estimated prevalence of 1-2 in 10,000. The genetic classification distinguishes the disorders due to defects in mtDNA from those due to defects in nuclear DNA.
Both mtDNA and nuclear mutations affecting OXPHOS usually result in multisystem clinical phenotypes, including peripheral neuropathy [2] . Peripheral neuropathy is a defining feature in some mitochondrial disorders such as SANDO (sensory ataxic neuropathy, dysarthria and minimum prevalence of peripheral neuropathy in patients with mitochondrial disorders, taking advantage of the large database built by the "Nation-wide Italian Collaborative Network of correlations are highlighted.
Methods
We reviewed the clinical data of all of the 1200 histologically, biochemically and/or molecularly defined patients present in our "Nation-wide Italian Collaborative Network of Mitochondrial Diseases" database (updated on December 31, 2014) and followed up by the involved centers, focusing on peripheral neuropathy as a clinical feature of a mitochondrial disorder.
The database establishment (and its use for scientific purposes) was permitted by the local Ethical Committees of the single centers, which obtained written informed consent from all patients or their tutors, and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. This project has been supported by a Telethon grant (GUP09004). This is a retrospective study; all the involved centers have specific expertise in mitochondrial disorders. The clinical section of our web-based database includes "yes or no" dichotomic items agreed by all centers in a preliminary consensus phase. The consensus phase was specifically designed to include the clinical features known to be relevant in mitochondrial medicine [1] . The presence or absence of neuropathy, and its specific type (i.e., axonal versus demyelinating, motor versus sensory, polyneuropathy versus multiplex neuropathy -including mixed forms [2] ) was requested to all centers for data elaboration. Clinical symptoms/ signs potentially suggestive of peripheral nerve dysfunction 
Results
The clinical picture was fully available for 1156 patients (mean age at onset 24.3 ± 20.1 years; age at last evaluation 39. 8 [3] , and occasionally is the prevalent frequent clinical manifestation (Table 1) . In 33 patients, disease manifestation [4, 5] . However, the exact prevalence of neuropathy was present at the onset of the disease. peripheral neuropathy in mitochondrial disorders is still
In order to understand if the presence (or absence) of unknown [6] .
peripheral neuropathy was linked to specific molecular or The aim of this retrospective study is to evaluate the clinical features, the patients of the Registry were divided in two groups, with and without neuropathy. Age at onset, age at last evaluation and gender ratio did not significantly differ between the two groups. Mitochondrial Diseases". Specific genotype-phenotype From a genotype-based point of view (Table 2) , the mtDNA mutations associated with Leber hereditary optic neuropathy (LHON) had the lowest frequency in the group with neuropathy. The same was also observed in those patients harboring single mtDNA deletions (p < 0.000003). In contrast, mutations in the nuclear genes POLG, SURF1 and TYMP were those most consistently associated with peripheral neuropathy (Table 2) . Table 1 Clinical features at the last evaluation in mitochondrial patients. The table shows the 15 most common features, present in at least 100 cases. Migraine, cardiomyopathy, retinopathy, respiratory impairment, gastrointestinal dysmotility, cataract, stroke-like episodes, myoclonus, tremor, parkinsonism, dystonia, dyskinesias, psychiatric involvement, vomiting, hypothyroidism, anemia were rarer (2-8%). From a phenotype-based point of view (Table 3) , patients with neuropathy had an increased prevalence of ataxia, hearing loss, muscle weakness and muscle wasting. There was neither association with other neuromuscular symptoms, such as exercise intolerance and muscle pain, nor with other multisystem features, in particular diabetes.
In those patients for whom muscle biopsy was available, ragged red fibers were equally frequent in the group with (67/ 96, 69.8%) or without (423/618, 68.4%) peripheral neuropathy. The same was observed for cytochrome c oxidase (COX)-negative fibers (81/96 [84.4%] and 470/618 [76.1%] respectively). Finally, considering the patients for whom plasma lactate levels were available, this biomarker was increased in 58/98 (59.2%) patients with and in 322/632 (50.9%) patients without neuropathy, again a non-significant difference.
Among our patients with neuropathy, the "pure" forms were rare. Specifically, 55 patients had a pure axonal neuropathy, 18 pure demyelinating, whereas 70 had a mixed/undefined pattern. Furthermore, 14 patients had a motor neuropathy, 26 a sensitive form, whereas the remaining patients had a mixed/undefined pattern. Finally, 94 patients have been defined as having a length-dependent polyneuropathy, three as a multiplex neuropathy, and the remaining 46 as a different/undefined pattern. Only 15 patients suffered of neuropathic pain.
The relative rarity of the pure forms precluded a strict genotype-phenotype analysis, but some indications (shown in Table 4 ) were noted; among the POLG-mutated patients, 9 had a pure axonal -sensory or sensory-motor -neuropathy and only one a pure demyelinating sensory neuropathy; the prevalence of neuropathic pain seemed more frequent in POLG patients than in mitochondrial patients with neuropathy due to different genetic causes (see Table 5 ).
Genotype-based approach. The patients have been divided in two groups, with and without neuropathy. Genotypes with less than ten patients have not been considered and are not shown. Significance levels after Bonferroni's correction 0.0042. Significant differences are represented in bold. LHON, Leber hereditary optic neuropathy. n.s., not significant difference.
Neuropathy:
Neuropathy: P No (n = 1013) Yes (n = 143) mtDNA single deletion mtDNA A3243G mutation mtDNA A8344G mutation mtDNA T8993G ( Table 3 Phenotype-based approach. The patients have been divided in two groups, with and without neuropathy. Genotypes with less than ten patients have not been considered and are not shown. Significance levels after Bonferroni's correction 0.0036. Significant differences are represented in bold. LHON, Leber hereditary optic neuropathy. n.s., not significant difference. n.s. Table 2  Table 4 Tentative phenotype-genotype correlations in mitochondrial neuropathy.
Neuropathy

POLG-associated neuropathy
Prevalence 19/45 (42.2%), in five cases from the onset High prevalence of neuropathic pain (>1/3 -see Table 5 ) 9 pure axonal, 1 pure demyelinating, 9 had mixed/undefined pattern 1 pure motor, 6 pure sensitive, 12 mixed/undefined pattern 11 length-dependent polyneuropathy, 1 multiplex neuropathy, 7 different/undefined pattern (axonal/mixed mainly sensory polyneuropathy)
TP (TYMP)-associated neuropathy
Prevalence 9/11 (81.8%), in no case from the onset Neuropathic pain is absent 2 pure axonal, 5 pure demyelinating, 2 had a mixed pattern 1 pure motor, 8 mixed sensori-motor pattern 8 length-dependent polyneuropathy, 1 different/undefined pattern (demyelinating sensory-motor polyneuropathy)
SURF1-associated neuropathy
Prevalence 10/20 (50.0%), in no case from the onset 3 pure demyelinating, 7 had a mixed/undefined pattern 1 pure motor, 9 mixed sensori-motor/undefined pattern 6 length-dependent polyneuropathy, 4 different/undefined pattern (demyelinating/mixed sensory-motor polyneuropathy)
m.8993T > G or T > C mutation-associated neuropathy
Prevalence 6/18 (33.3%), in one case from the onset 5 pure axonal, 1 mixed/undefined 3 pure sensory, 3 mixed/undefined 5 length-dependent polyneuropathy, 1 different/undefined pattern (axonal, mainly sensory polyneuropathy) 
Discussion
Despite the great progress in our genetic and clinical understanding of mitochondrial disorders, the prevalence of peripheral neuropathy is still unknown. Most of the published studies have examined single cases or families, or have been conducted by recruiting a limited number of patients [7] . Girlanda et al. analyzed 27 patients with unselected mitochondrial disease, and observed axonal neuropathy in six cases (18%) [8] . Mancuso et al. [9] showed electrophysiologically that peripheral neuropathy was present in about 35% of unselected mitochondrial patients, even if the peripheral nerve involvement was frequently subclinical. In the present study, taking advantage of a very large unselected cohort of mitochondrial disorders patients, including LHON and oligosymptomatic forms, we found a lower prevalence of peripheral neuropathy (12,4%), which could represent the minimum prevalence of peripheral neuropathy in mitochondrial disorders (13.5% [142/1052] if we exclude the patients with LHON).
This preliminary survey presents the typical limitations of all retrospective studies, and may underestimate the real prevalence of neuropathy in patients with mitochondrial disorders. However, all the involved centers have strong expertise in clinical and electrophysiological assessment of neuromuscular disorders, which should minimize false negative or positive cases. Previous surveys [7] [8] [9] , specifically designed for assessing the involvement of peripheral nervous system, also included patients with subclinical neuropathy, a criterion which can partially account for the discrepancy with the data presented here.
Recently, Horga et al. [10] reported that peripheral neuropathy might suggest a nuclear gene defect in patients with mitochondrial progressive external ophthalmoplegia (PEO). In this study, 67% of PEO patients had a single mitochondrial DNA deletion, whereas 10% had a point mutation of mtDNA and 22% had mutations in either POLG, C10orf2, RRM2B, or had multiple mtDNA deletions in muscle without an identified nuclear gene defect. The prevalence of peripheral neuropathy was significantly lower in patients with single, sporadic mitochondrial DNA deletion (2%) as compared to those with a mtDNA point mutation or with a nuclear DNA defect (44% and 52%, respectively; P < 0.001) [10] . Therefore, our results confirm the suggestion by Horga et al., that in PEO patients peripheral neuropathy is rarely found in association with single mtDNA deletions, whereas it is highly predictive of an underlying nuclear DNA defect [10, 11] . Indeed, our data extend this concept to the entire population of mitochondrial patients, in addition to those with PEO; furthermore, we show that a "mitochondrial neuropathies" are predominantly associated with a few specific nuclear genes associated: POLG, TYMP and SURF1. This observation may facilitate the development of diagnostic algorithms suggesting nuclear gene testing in patients with mitochondrial disease and peripheral neuropathy, for a more rapid diagnosis, which can be achieved without performing a muscle biopsy.
Furthermore, peripheral neuropathy with anesthesia leading to corneal scarring and acral mutilations is one of the major clinical features of Navajo neurohepatopathy, an autosomal recessive hepato-cerebral mtDNA depletion syndrome caused by a mutation in the MPV17 gene [12] .
In our cohort, the subjects with neuropathy had an increased prevalence of ataxia, hearing loss, muscle weakness and muscle wasting. Therefore, neuropathy can cause and/or exacerbate neuromuscular symptoms that have a strong impact on the quality of life of these patients.
Some phenotype-genotype correlations were highlighted in our study. In particular, POLG mutations can cause a potentially painful, axonal/mixed, mainly sensory polyneuropathy; TYMP mutations can lead to a demyelinating sensory-motor polyneuropathy (usually in the context of the MNGIE syndrome); SURF1 mutations lead to a Leigh (or Leigh-like) phenotype frequently associated with a demyelinating/mixed sensory-motor polyneuropathy.
In our cohort, the only mtDNA mutation potentially associated with neuropathy is the m.8993T > G (or T > C) change, which can lead to an axonal, mainly sensory polyneuropathy.
In conclusion, peripheral neuropathy is one of ten most common features of mitochondrial disease that potentially have a strong impact on the quality of life of these patients. Some genotype-phenotype correlations were highlighted, and the presence or absence of peripheral neuropathy, as well as its specific form and the association with neuropathic pain (indicative of a POLG-associated disease) can guide the molecular analysis.
Prospective studies on clinical features in mitochondrial disorders are strongly needed; however, large multicenter retrospective studies help to characterize the clinical picture and natural history of rare diseases such as mitochondrial disease, and represent the basis for planning more rigorous longitudinal studies.
